Showing 3901-3910 of 7278 results for "".
- New World Market for Prescription Dermatological Drugs Report Releasedhttps://practicaldermatology.com/news/new-world-market-for-prescription-dermatological-drugs-report/2458749/Research and Markets recently added the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer,Melasma and Seborrhea Treatments)&qu
- Advancing Age May Affect Psoriasis Patients' Access to Biologicshttps://practicaldermatology.com/news/advancing-age-may-affect-psoriasis-patients-access-to-biologics/2458746/Elderly psoriasis patients may be less likely to receive biologics, according to a new study out of Umeå University in Sweden. Specifically, an age increase of 30 years resulted in an average 65 percent reduction in likelihood of obtaining treatment with biologics in this population
- Study Highlights Risk Factors for cSCC Recurrence, Metastasis and Deathhttps://practicaldermatology.com/news/study-highlights-risk-factors-for-cscc-recurrence-metastasis-and-death/2458753/Tumor depth confers the highest risk of local recurrence and metastasis of cutaneous squamous cell carcinoma (cSCC) and tumor diameter exceeding 20 mm is associated with the highest risk for disease-specific death, a new study suggests. The findings are published online in
- New Blood Test Gets Leg Up On Advanced Melanomahttps://practicaldermatology.com/news/new-blood-test-gets-leg-up-on-advanced-melanoma/2458756/A blood test that monitors blood levels of DNA fragments from dead cancer cells may be better at tracking progression of metastatic melanoma than the current standard blood test. The standard test measures blood levels of the enzyme lactate dehydrogenase (LDH), which tend t
- Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and Canadahttps://practicaldermatology.com/news/galderma-laboratories-lp-appoints-miles-harrison-as-leader-of-us-and-canada/2458762/Galderma promoted Miles Harrison to President and General Manager of Galderma Laboratories, L.P. leading the US and Canada teams. Miles Harrison joined Galderma US in 2014 as the Vice President
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- ASDS Honors Dr. Ian Maher for Outstanding Servicehttps://practicaldermatology.com/news/asds-honors-dr-ian-maher-for-outstanding-service/2458764/The American Society for Dermatologic Surgery (ASDS) last month presented Ian A. Maher, MD, of St. Louis with the ASDS Award for Outstanding Service. The award is given annually to one member who has volunteered his or her time for multiple Society projects or initiatives. In an effort to recogni
- Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absencehttps://practicaldermatology.com/news/valeant-announces-j-michael-pearson-will-be-on-medical-leave-of-absence/2458770/Valeant Pharmaceuticals International, Inc. announced that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective immediately. The company's board of directors has created an Office of the Chief Executive Officer, which will include Robert Cha
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat